Plain Language Summary
What is this summary about?
This is a plain language summary of a guideline on the management of stage 3 non-small-cell lung cancer, also known as NSCLC. This guideline was written by the American Society for Clinical Oncology (ASCO for short) and published in the Journal of Clinical Oncology.
Why were the guidelines developed?
The purpose of the ASCO guideline is to provide recommendations to healthcare professionals in the US including oncologists, surgeons, pathologists, radiologists, and nurses on how best to diagnose and treat people with stage 3 NSCLC.
How were the guildeines developed?
The ASCO guideline is based on the latest research and scientific evidence to make certain the recommendations are up to date and based on reliable data and best practice. In 2021, a group of experts were asked by ASCO to form an Expert Panel. The Expert Panel reviewed the results of 127 clinical research studies on NSCLC that were done between 1990 and 2021. They looked at how NSCLC had been diagnosed and treated in these studies, as well as at patients' survival and quality of life. The Expert Panel used these findings and their own expertise to form their recommendations and produce the 2021 ASCO Guideline called ‘Management of Stage 3 Non-Small-Cell Lung Cancer: ASCO Guideline’.
What information does the guideline contain?
The guideline aims to answer the following questions:
What are the most precise ways to confirm and stage NSCLC in people suspected of having a stage 3 disease?
Which patients with stage 3 NSCLC can be treated most successfully with surgery?
Which patients who can be treated with surgery could also have an additional therapy before their surgery?
Which patients who can be treated with surgery could also have an additional treatment after their surgery?
Which treatment and/or management is most suitable for patients who cannot have surgery?
Keywords: : lay summary, NSCLC, plain language summary, stage III
To read the full Plain Language Summary of this article, click here to view the PDF.
Link to original article here
https://ascopubs.org/doi/full/10.1200/JCO.21.02528
Acknowledgments
This article was selected by a Steering Committee, put together by the Future Science Group, who identified specific articles to be explained as a plain language summary to help educate about the latest developments in non-small cell lung cancer. The authors would like to thank the Steering Committee for their role in this selection process. Medical writing assistance was provided by Catherine Barras, MSc and Danielle Birchall, MRes MICR, of Simplifying Science® and was supported financially by Future Science Group, through an Independent Medical Education Grant provided by Pfizer, Inc. Simplifying Science® is a registered trademark in Great Britain and Northern Ireland. Trademark No. UK00003709258. Owned by and registered to Lay Writing Services Ltd.
Financial & competing interests disclosure
The Steering Committee were compensated for their time in the process of article selection as described above. The authors did not receive payment related to the development of the plain language summary of publication.